NuPathe has a collaborative relationship with the University of Pennsylvania concerning our LAD, or long-acting delivery technology. This long-term biodegradable implant technology is used in two of our product candidates, NP201 and NP202. NuPathe retains the exclusive, worldwide rights for this technology.
NuPathe has a collaboration agreement with Evonik Industries AG, Inc. for the development of the LAD technology combined with the active ingredient, ropinirole, for use in the company’s NP201 candidate for Parkinson’s disease. NuPathe retains the exclusive, worldwide rights to NP201.
NuPathe has a development and license agreement with LTS Lohmann Therapie-Systeme AG for the manufacture of our Zecuity clinical supplies.